Japan· JP-1229405A2024
ロクロニウム臭化物
A rocuronium bromide product containing ロクロニウム臭化物, registered in Japan by ＭＳＤ, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Rocuronium bromide is registered in 13 of 19 countries.
Countries holding a registration under ATC M03AC09 (rocuronium bromide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Rocuronium bromide · ATC M03AC09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ロクロニウム臭化物
- Manufacturer
- ＭＳＤ
- Country
- Japan (JP)
- ATC code
- M03AC09
- ATC class
- Rocuronium bromide
- Defined daily dose
- 42 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
109 interactions on record for rocuronium bromide.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rocuronium bromide · interactions on record
109 records
- 12 severe
- 59 moderate
- 4 minor
- 34 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- ParomomycinA07AA06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under M03AC09
Rocuronium bromide, as other registers publish it.
- FinlandEsmeronMerck Sharp & Dohme B.V.
- PolandEsmeronMSD Polska Sp. z o.o.
- PolandEsmeronMSD Polska Sp. z o.o.
- FinlandEsmeronOrifarm Oy
- CzechiaESMERONMerck Sharp & Dohme B.V., Haarlem
- CzechiaESMERONMerck Sharp & Dohme B.V., Haarlem
- CzechiaESMERONMerck Sharp & Dohme B.V., Haarlem
- CzechiaESMERONMerck Sharp & Dohme B.V., Haarlem
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e4d03715-02ce-4a8b-a8f2-deb4f170b078 GET /v1/drugs/e4d03715-02ce-4a8b-a8f2-deb4f170b078?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1229405A2024",
"category": "注射薬",
"price_yen": 488,
"generic_name": "ロクロニウム臭化物",
"product_name_jp": null,
"therapeutic_class": "1229",
"transitional_expiry": null
}See everything about rocuronium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.